ascendis transcon glp-1 program Novo Nordisk taps in $285 million deal press #icymi #ascendispharma #transcontechnology |
Description
Savidge TC, Newman P, Pothoulakis C, et al
Venoms, in particular, represent an unexplored pharmacopeia
[No authors listed] Effect of intensive therapy on residual -cell function in patients with type 1 diabetes in the diabetes control and complications trial
Dont neglect your nutrient intake
The altered intestinal pathway after bypass can amplify GLP-1 effects because the medication directly stimulates remaining digestive tissue at higher local concentrations
Available from: Bourgin D
